EVALUATION OF THE RESPONSIBILITY OF HEPATOCELLULAR CARCINOMA AFTER TACE AT THAI NGUYEN ONCOLOGY CENTER

Nguyễn Quang Hưng; Nguyễn Trường Giang; Hoàng Minh Cương

doi:10.34238/tnu-jst.9232

EVALUATION OF THE RESPONSIBILITY OF HEPATOCELLULAR CARCINOMA AFTER TACE AT THAI NGUYEN ONCOLOGY CENTER

About this article

Received: 15/11/23 Revised: 05/01/24 Published: 03/02/24

Authors

1. Nguyen Quang Hung, Thai Nguyen National Hospital
2. Nguyen Truong Giang, Thai Nguyen National Hospital
3. Hoang Minh Cuong , TNU - University of Medicine and Pharmacy

Abstract

A cross-sectional descriptive study was used on 58 patients diagnosed with hepato-cellular carcinoma receiving transarterial chemoembolization with Lipiodol and Doxorubicin at Thai Nguyen Central Hospital from August 2016 to August 2020. The study objective is to evaluate the response of tumors after receiving transarterial chemoembolization. The most tumors were supplied by the visceral artery, accounting for 91.4%, transarterial chemoembolization technique was mainly performed on one tumor, accounting for 70.7%. After chemoembolization, the rate of tumors with vascular proliferation decreased, at the time before embolization, this rate was 77.6% (45/58). After six months of embolization, this rate was 17.9% (7/39). After transarterial chemoembolization, tumor’s size decreased. Before embolism, 32.8% of patients had tumor size ≤ 5 cm; after a period of 1 month, 3 months, and 6 months, the proportion of patients with tumor size ≤ 5 cm were 38.6%, 51.1% and 61.5%, respectively. The average size of the tumor before transarterial chemoembolization was 71.2 ± 27.5 mm. After 1 month, the average was 67.9 ± 25.9 mm. Research results show that, Transarterial chemoembolization was an effective method for treating hepato-cellular carcinoma. Transarterial chemoembolization is mostly applied for only one feeding vessel. After the procedure, the tumor’s size decreased time by time.

Keywords

Hepato-cellular carcinoma; Transarterial chemoembolization; Response; Treatment; Tumor

Full Text:

PDF (Tiếng Việt)

References

[1] H. Sung et al., “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA Cancer J Clin, vol. 71, no. 3, pp. 209-249, 2021.

[2] WHO, “Globocan 2020 - Viet Nam,” 2021. [Online]. Available: https://gco.iarc.fr/today/data/factsheets/populations/704-viet-nam-fact-sheets.pdf. [Accessed Nov. 15, 2023].

[3] H. S. D. Nguyen et al., “High burden of hepatocellular carcinoma and viral hepatitis in Southern and Central Vietnam: Experience of a large tertiary referral center, 2010 to 2016,” World J Hepatol, vol. 10, no. 1, pp. 116-123, 2018.

[4] S. B. Eldad and M. B. Adrian Di, “Diagnosis of hepatocellular carcinoma,” HPB : the official journal of the International Hepato Pancreato Biliary Association, vol. 7, no. 1, pp. 26-34, 2005.

[5] J. A. Marrero et al., “Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases,” Hepatology, vol. 68, no. 2, pp. 723-750, 2018.

[6] E. Kotsifa et al., “Transarterial Chemoembolization for Hepatocellular Carcinoma: Why, When, How?” J Pers Med, vol. 12, no. 3, p.436, 2002.

[7] N. Manjunatha et al., “Transarterial Chemoembolization and Unresectable Hepatocellular Carcinoma: A Narrative Review,” Cureus, vol. 14, no. 8, 2022, Art. no. e28439.

[8] J. L. Raoul et al., “Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence,” Cancer Treat Rev, vol. 72, pp. 28-36, 2019.

[9] H. Ghanaati, M. Mohammadifard, and M. Mohammadifard, “A review of applying transarterial chemoembolization (TACE) method for management of hepatocellular carcinoma,” J Family Med Prim Care, vol. 10, no. 10, pp. 3553-3560, 2021.

[10] Ministry of Health, Guidelines for diagnosis and treatment of hepatocellular carcinoma, Issued together with Decision No. 3129/QD-BYT dated July 17, 2020, 2020.

[11] A. Tsoris and C. A. Marlar, “Use Of The Child Pugh Score In Liver Disease,” 2020. [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK542308/. [Accessed Nov. 15, 2023].

[12] S. W. Shin, “The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma,” Korean J Radiol, vol. 10, no. 5, pp. 425-434, 2009.

[13] Y. Asayama et al., “Arterial Blood Supply of Hepatocellular Carcinoma and Histologic Grading: Radiologic-Pathologic Correlation,” American Journal of Roentgenology, vol. 190, no. 1, pp. W28-W34, 2008.

[14] L. C. Nguyen and N. M. Nguyen, “Evaluating the effectiveness of arterial chemical embolization in patients with hepatocellular carcinoma,” Vietnam Medical Journal, vol. 512, no. 1, pp. 36-38, 2002.

[15] N. Matsuo et al., “Optimal lipiodol volume in transcatheter arterial chemoembolotherapy for hepatocellular carcinoma: study based on lipiodol accumulation patterns and histopathologic findings,” Semin Oncol, vol. 24(2 Suppl 6), pp. S6-61-s6-70, 1997.

[16] T. D. Nguyen, T. M. Pham, and C. H. Trieu, “Imaging characteristics and results of chemical embolization of hepatocellular carcinoma in patients under 40 years old,” Journal of Radiology & Vietnam nuclear medicine, vol. 2022, no. 43, pp. 63-70, 2002.

[17] S. Ako et al., “Transcatheter Arterial Chemoembolization to Reduce Size of Hepatocellular Carcinoma before Radiofrequency Ablation,” Acta Med Okayama, vol. 72, no. 1, pp. 47-52, 2018.

[18] T. Q. Nguyen, “Evaluating the results of treatment of primary liver carcinoma by petrochemical liver embolization method at Viet Tiep Hospital, Hai Phong,” Master thesis, Hanoi Medical University, pp. 87, 2014.

[19] A. A. Zeeneldin et al., “Transarterial chemoembolization for the treatment of hepatocellular carcinoma: A single center experience including 221 patients,” Journal of the Egyptian National Cancer Institute, vol. 25, no. 3, pp. 143-150, 2013.

DOI: https://doi.org/10.34238/tnu-jst.9232

Refbacks

There are currently no refbacks.



Remember me